INTRODUCTION
to the etiopathology of schizophrenia. In this article, we reviewed current evidences suggesting the association between neuroprotection and schizophrenia in the etiological and therapeutic perspectives.
NEUROINFLAMMATION AND NEUROGENESIS OF SCHIZOPHRENIA
Inflammation has been considered to be a causative factor in schizophrenia, which has been shown to involve a dysregulated cytokine system. Cytokines are pleiotropic glycoproteins produced by both peripheral immune cells and glial cells in the brain. 15, 16 Cytokines usually have an important role in mediating immune signals and inflammatory processes in the peripheral system and in the brain; cytokines also are involved in various neural interactions such as neurogenesis and synaptic plasticity. 17, 18 In this regard, neuroinflammation is distinguished from systematic inflammation. Particularly, pro-inflammatory cytokines such as interleukin-1β (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α) primarily mediate and facilitate neural activities as well as inflammatory processes. In particular, during the early period of disease development, activated pro-inflammatory cytokines may exert detrimental effects on the brain. There is mounting evidence that prenatal exposure to pro-inflammatory cytokines induces impaired spatial memory, neuronal loss, and gliosis in the hippocampus. 19 Moreover, neurodevelopmental injuries due to excessive pro-inflammatory cytokines increase susceptibility to schizophrenia. [20] [21] [22] Neurogenesis is defined as a coordinating process of generating new neurons from neural stem cells. 23 Since the first report from animal studies 24 and human postmortem studies of the hippocampal region, 25 numerous studies have focused on adult neurogenesis. Neurogenesis consists of many steps including stem cell proliferation, neuronal differentiation, migration, and ultimately, integration of newly generated neurons into functional neuronal circuitry. 26 Adult neurogenesis occurs in specific regions including the subventricular zone (SVZ) in the lateral ventricle and the subgranular zone (SGZ) in the dentate gyrus of the hippocampus. Generally, adult hippocampal neurogenesis is significantly and positively associated with cognitive function such as learning and memory function, which are mainly processed in the hippocampus. [27] [28] [29] [30] [31] Several studies have shown that newly-generated neurons in adulthood have a role in synaptic plasticity and cognitive functions in psychiatric diseases including depression and schizophrenia. 26, 30, 32 To date, the most widely investigated psychiatric illness in terms of neurogenesis is probably major depressive disorder, although the pathophysiological link is still uncertain. [33] [34] [35] Importantly, pervasive cognitive dysfunction that does not adequately respond to antipsychotics is a distinguishing clinical characteristic of schizophrenia. [36] [37] [38] In fact, there is a possibility that specific molecular and cellular dysfunction in the hippocampus contributes to the development of schizophrenia. 39 Additionally, decreased hippocampal volume and activity are the most consistent findings of neuroimaging studies of schizophrenia. 40, 41 One previous study has revealed that impaired prefrontal-hippocampal connectivity is associated with impaired spatial working memory in schizophrenia. 42 In addition, in a postmortem study of human psychiatric patients, neural stem cell proliferation in the dentate gyrus was only impaired in patients with schizophrenia, but not in those with depression. 43 Another postmortem study revealed that the number of dividing cells is decreased in the SGZ of patients with schizophrenia. 44 Collectively, molecular and neuroanatomical evidence supports the notion that hippocampal adult neurogenesis is closely associated with schizophrenia.
Interestingly, neurogenesis is closely associated with pro-inflammatory cytokines and neuroinflammation. Pro-inflammatory cytokine receptors are highly aggregated in regions associated with cognitive functioning such as the hippocampus. 45, 46 Pro-inflammatory cytokines and their receptors may inhibit neurogenesis and impair cognitive function. 47, 48 Numerous reports have supported the idea that several pro-inflammatory cytokines affect neurogenesis.
IL-1β has been consistently shown to be associated with neurogenesis in brain, especially in the hippocampal region. 49, 50 It is of note that the inhibition of IL-1β blocks the decrease in neurogenesis caused by acute stress, as well as the anhedonic and antineurogenic effects of chronic stress. 49 A previous study revealed that sustained hippocampal IL-1β expression has a detrimental effect on adult neurogenesis. 51 IL-1β is also known to be involved in the IFN-γ-induced suppression of neurogenesis. 52 Leukemia inhibitory factor (LIF) is also an important cytokine involved in schizophrenia. LIF shares glycoprotein 130 (gp130) with other IL-6 cytokine family members. 53 LIF mainly modulates neuronal activity such as glial cell activity, the inflammatory process, transcription pathways, and neurogenesis. [54] [55] [56] An appropriate amount of LIF is essential for normal neuronal function. In an animal study, LIF knock-out mice showed decreased astrocyte and microglial cell activities compared to wild type mice. 54 Various insults to the CNS may induce over-expression of LIF, which may lead to neurobehavioral abnormalities similar to schizophrenia. 56 Additionally, LIF gene polymorphism is associated with susceptibility to schizophrenia and working memory deficit. 57 Another cytokine, TNF-α, has an important role in neuronal activity in the CNS. 58, 59 TNF-α is usually maintained at low level under normal physiological conditions. 60 However, when the microenvironment in the CNS is altered by injuries such as physical head trauma, infection, and ischemic attack, TNF-α is activated by glial cells. 61, 62 Interestingly, TNF-α has a pivotal role in mediating neurogenesis via its receptors, tumor necrosis factor receptor (TNFR)-1 and TNFR-2. Those two receptors are different in several aspects. First, TNFR-1 contains an intracellular 'death domain' and is involved in detrimental effects such as neuronal apoptosis and neurodegeneration, whereas TNFR-2 is usually involved in neuroprotection. 63, 64 Thus, TNFR-1 and TNFR-2 are differentially involved in proliferation and differentiation of hippocampal neural stem cells. TNFR-1 exerts a negative influence on hippocampal adult neurogenesis, [65] [66] [67] whereas TNFR-2 is involved in promoting neurogenesis. 68, 69 TNF-α is also closely associated with synaptic plasticity by inducing α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors that mediate glutamatergic activity. 70 Because human neural stem cells have both TNFR-1 and TNFR-2, whether neurogenesis is enhanced or inhibited depends on the microenvironment in the CNS and the context of insults.
OXIDATIVE STRESS AND MITOCHONDRIAL DYSFUNCTION IN SCHIZOPHRENIA
Neuroinflammation is closely associated with excessive oxidative stress. 71, 72 The CNS is more vulnerable to oxidative stress than are other organs. The brain consumes large amounts of oxygen, lacks anti-oxidative compounds, has a high ratio of membrane surface area to cytoplasmic volume, has a high concentration of polyunsaturated fatty uric acids, and contains a large amount of metals. [73] [74] [75] [76] There have been many evidences suggesting that neuroinflammation and oxidative stress have close interactions and play an important role in the pathophysiology of schizophrenia. [77] [78] [79] Reactive oxygen species (ROS), which include superoxide, nitric oxide, and hydrogen peroxide, are highly reactive molecules, and free radicals are naturally created as byproducts of electron transport and energy metabolism. Appropriate duration and amount of ROS activity contribute to enhanced cellular functioning. 80 However, an imbalance between amounts of ROS and antioxidant system products can result in oxidative damage. 81 An imbalance between oxidative stress and antioxidants is also demonstrated in schizophrenia. 82, 83 Several studies have reported excessive activity of oxidants 84 and decreased antioxidants in patients with schizophrenia. 85 Antioxidants consist of enzymatic and non-enzymatic materials. Enzymatic antioxidants include superoxide dismutase (SOD), catalase, and glutathione dismutase. Non-enzymatic antioxidants are albumin, uric acid, bilirubin, vitamin C, vitamin E, and β-carotene. In particular, glutathione plays a major role in the redox process. 86 Glutathione exerts various effects in the CNS including directly detoxifying drugs, ROS, and electrophilic xenobiotics; storing cysteine; promoting neurodevelopment; and enhancing excitatory glutamatergic neurotransmission. [87] [88] [89] The possible actions by which a deficit of glutathione contributes to the development of schizophrenia may be through NMDA receptors. Dysregulation of dopaminergic neurotransmission and hypofunction of NMDA receptor activity are regarded as the core mechanisms of schizophrenia. 90 Under normal physiological conditions, glutathione enhances NMDA receptor-mediated glutamatergic neurotransmission. Many animal studies have reported that glutathione exerts an agonistic effect on NMDA receptors. 87, 91 However, in the presence of uncontrolled and persistent chronic oxidative stress, glutathione level is decreased and leads to NMDA receptor dysfunction. 92, 93 Deficits in glutathione level are associated with neurological deficits in various neuropsychiatric diseases. 94 Glutathione regulates redox-sensitive sites such as the NMDA receptor. Further, a key glutathione-synthesizing enzyme, glutathione cysteine ligase modifier (GCLM), is decreased under oxidative stress. 95 GCL dysregulation and deficit glutathione inhibit the detoxification of oxidative stress that results from dopamine metabolism and consequently lead to neural injury, especially in dopamine neuron-rich regions. 96, 97 Glutathione is reduced in the prefrontal cortex and striatum, 94, [98] [99] [100] which are closely associated with the psychopathology of schizophrenia. Many studies have shown that a deficit in glutathione is associated with psychopathology and clinical variables in schizophrenia. [100] [101] [102] Mitochondrial dysfunction, which is closely associated with oxidative stress, is also associated with neurodegenerative change in schizophrenia. Mitochondria are mainly involved in producing energy via the electron transport chain during the process of oxidative phosphorylation. Mitochondria also regulate intracellular calcium homeostasis and apoptosis. Neurons require the large amount of energy that is mainly produced by the mitochondrial respiratory system in order to maintain the ion gradient between the extracellular and intracellular membranes. Several studies have reported that genetic and structural abnormalities of mitochondria are associated with various psychiatric diseases. 103, 104 In particular, psychosis and cognitive deterioration are common features of mitochondrial diseases such as mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (ME-LAS) syndrome. 105 Mitochondrial metabolism is also important for producing ROS. In particular, mitochondrial DNA is vulnerable to oxidative stress because it is located in the mitochondrial inner membrane, where a substantial amount of ROS is produced.
Mitochondrial injury and oxidative stress form a vicious cycle. Mitochondria injured by excessive oxidants produce a greater amount of ROS, which leads them to be more vulnerable to oxidative stress. 107 For example, an overload of oxidative stress causes lipid peroxidation. Lipid peroxidation of the mitochondrial membrane produces toxic molecules such as 4-hydroxynonenal and malondialdehyde, which in turn disturb mitochondrial membrane fluidity. 108, 109 The impaired mitochondrial membrane leads to dysregulation in ionic balances and excessive intracellular calcium influx, which consequently causes neuronal death and impairs synaptic plasticity.
110-112

NEUROPROTECTIVE AND ANTI-INFLAMMATORY THERAPY IN SCHIZOPHRENIA
Randomized controlled trials have investigated the efficacy of adjuvant COX-2 inhibitor on antipsychotics treatment in schizophrenia. Of the four extant studies, three have reported significant improvement in psychopathology, [113] [114] [115] whereas one study showed no significant efficacy of COX-2. 116 An improvement in psychiatric symptoms with anti-inflammatory treatment may be associated with the duration of illness. Whereas the three studies finding a significant therapeutic efficacy of the COX-2 inhibitor were based on patients with a short illness period, [113] [114] [115] the one study with a negative result was conducted with patients with relatively chronic schizophrenia. 
Non-comparative, one sample
Atypical antipsychotics (clozapine, risperidone, olanzapine, quetiapine, ziprasidone) treatment significantly reduced serum malondialdehyde and superoxide dismutase levels in schizophrenia after 8 weeks.
Wang et al.
In vitro (PC12 cells) Olanzapine and quetiapine reduced intracellular reactive oxygen species caused by β-amyloid. Olanzapine and quetiapine completely prevented β-amyloid-induced reduction of glutathione peroxidase.
Padurariu et al.
Cross-sectional, case-control Glutathione peroxidase specific activity and malondialdehyde levels were significantly higher in all antipsychotics (haloperidol, olanzapine, quetiapine, risperidone) groups than healthy controls. Superoxide dismutase specific activity was significantly higher in haloperidol and quetiapine than healthy controls.
Park et al.
In vitro (PC12 cells) Aripiprazole significantly reduced 1-methyl-4-phenylpyridinium-induced cell death. Olanzapine, aripiprazole, and ziprasidone significantly increased superoxide dismutase activity, whereas haloperidol had no significant effects.
Study Intervention Main findings
Therapeutic effects of antioxidants in schizophrenia Beck et al.
NAC 2 g/day NAC significantly improved negative symptoms, but not positive symptoms than placebo. NAC significantly improved akathisia.
Lavoie et al.
NAC 2 g/day NAC significantly improved mismatch negativity of the encephalograph than placebo.
Carmeli et al.
NAC 2 g/day NAC significantly increased multivariate phase synchronization in the left parieto-occipital, right temporalm bilateral prefrontal regions than placebo.
NAC: N-acetyl cysteine
A meta-analysis showed that augmentation of anti-inflammatory drugs to the antipsychotics would be a potential therapeutic options in patients with schizophrenia, although more evidences should be accumulated. 117 Several antioxidant treatment approaches have reported that antioxidants are effective for improving psychopathology in schizophrenia. Because glutathione is not bioavailable, it is not possible to able to be directly used. Instead, N-acetyl cysteine (NAC), which is a glutathione precursor, has been used for schizophrenic patients. A double-blind, placebo-controlled study demonstrated that NAC (2 g/day) ameliorated negative symptoms, but not positive symptoms in patients with chronic schizophrenia. 118 Another double-blind, placebo-controlled study revealed that NAC improved mismatch negativity, which is associated with NMDA receptor function, in patients with schizophrenia. 119 Several studies have consistently reported that ginkgo biloba augmented with haloperidol improves negative symptoms and increases SOD level in patients who experience chronic hospitalizations and treatment resistance due to schizophrenia. [120] [121] [122] A meta-analysis revealed that ginkgo as an add-on treatment to antipsychotics significantly improved total and negative symptoms in patients with chronic schizophrenia. 123 Several studies have reported that schizophrenia is associated with low serum vitamin C levels. [124] [125] [126] A previous doubleblind, placebo-controlled study showed that a vitamin C (500 mg/day) supplement with atypical antipsychotics (olanzapine 10 mg/day, quetiapine 200 mg/day, or ziprasidone 40 mg/day) significantly decreased serum malondialdehyde (MDA) level and psychopathology compared to a placebo add-on group. 127 Antipsychotics have been thought to have anti-inflammatory properties. In a meta-analysis of patients with acute relapse or first onset schizophrenia, levels of peripheral pro-inflammatory cytokines including IL-6, IL-1β, and IFN-γ were significantly decreased after antipsychotic treatment compared to baseline. 128 Those results are in line with previous studies reporting that both typical and atypical antipsychotics suppress microglial activation, thus inhibiting inflammatory mediators. [129] [130] [131] [132] [133] Antipsychotics also enhance neurogenesis. In one study, chronic treatment with a low dose of clozapine (0.5 mg/kg) increased the number of bromodeoxyuridine (BrdU)-positive cells in the dentate gyrus 24 hours after BrdU administration, whereas haloperidol (0.05 or 2 mg/kg) or a high dose of clozapine (20 mg/kg) had no significant effect. 134 Interestingly, the increased BrdU-positive cells with a low dose of clozapine could not survive or integrate into existing hippocampal circuitry. These intriguing results suggest that antipsychotics influence neuronal proliferation, but not survival. It has been speculated that the limitations of the effect of antipsychotics on neurogenesis may be associated with an insufficient treatment response in terms of negative and cognitive symptoms, as well as a deteriorating course of schizophrenia. At the same time, antipsychotics demonstrate antioxidant effects. [135] [136] [137] [138] One study group has consistently reported that initial SOD level in schizophrenia was lower than that in controls, and both typical and atypical antipsychotics significantly increase SOD level. 72, [139] [140] [141] The improvement in the psychopathology of patients with schizophrenia has been correlated with the degree of change in SOD level. Although the mechanisms by which antipsychotics exert antioxidant effects still have not been clearly identified, differences between typical and atypical antipsychotics appear insignificant. 135, 141 The aforementioned evidences supporting the relationships between oxidative stress and schizophrenia were summarized in Table 1 . 
CONCLUSION
Current evidence clearly supports a close link between neuroprotection and the onset and symptoms of schizophrenia. Several factors affecting neuroprotection, which include neuroinflammation, neurogenesis, and oxidative stress, appear to increase vulnerability to schizophrenia (Figure 1) . However, there are several issues in the field of neuroprotection in schizophrenia. First, the measurements of pro-inflammatory cytokines, oxidative stress markers, and neural cell proliferations may not suitable for distinguishing schizophrenia from other neuropsychiatric diseases. Second, despite several clinical findings supporting the effectiveness of adjuvant antioxidant and anti-inflammatory agents, further longitudinal studies and studies with a large sample are needed. Third, the heterogeneous subtypes of schizophrenia should also be considered limiting factors of schizophrenia-specific findings.
